CTN Bulletin logo
July 2, 2018

Helping to End Addiction Long-Term (HEAL) Initiative



HEAL initiative logoIn a Viewpoint published last month in the Journal of the American Medical Association, National Institutes of Health leadership detail components of a newly released research plan for the Helping to End Addiction Long-term (HEAL) Initiative. The HEAL Initiative is a trans-NIH effort launched in April 2018 to advance national priorities in addressing the opioid crisis through science. With a focus on two primary area -- improving treatments for opioid misuse and addiction, and enhancing strategies for pain management -- the plan describes a multifaceted program encompassing pre-clinical, clinical, drug repurposing, and community-based approaches.

NIH outlines initial investments of the $500 million appropriated by Congress for fiscal year 2018 to bolster NIH’s research efforts in addiction and pain. Critical components of the HEAL research plan for FY2018 include:

  • Developing extended-release and longer-acting opioid use disorder (OUD) medications and new therapies to counteract opioid-induced respiratory depression.
  • Reformulating current medication-assisted treatments (MAT) to promote adherence to recovery programs by Americans on OUD medications.
  • Supporting discovery and development of targets for non-addictive pain management, and therapies to treat those targets.
  • Collecting data to determine what factors lead acute pain to transition to chronic pain and how to block that transition.
  • Partnering with public and private groups to test effective treatments for pain and addiction using HEAL’s clinical trial networks.
  • Expanding NIH’s Advancing Clinical Trials in Neonatal Opioid Withdrawal syndrome (ACT NOW) to assess its prevalence and determine best practices for clinical care of infants with this condition.
  • Advancing new models of care for OUD and test integrated, evidence-based interventions within healthcare and criminal justice settings through the multi-site HEALing Communities initiative.

ARTICLE: Collins FS, Koroshetz WJ, Volkow ND. Helping to End Addiction Over the Long-term: The Research Plan for the NIH HEAL Initiative. JAMA 2018. doi:10.1001/jama.2018.8826

CTN Trial Progress

GraphStudy results for Open Studies as of the July 1 trial Progress Report.

CTN-0064 - Linkage to HCV Care.
Enrolled 113

CTN-0067 - CHOICES Scale-Up. Enrolled 25

CTN-0068 - ADAPT-2 for Methamphetamine Use Disorder. Enrolled 212

CTN-0069 - OUD in the Emergency Department. Enrolled 337

CTN-0073 - Detecting Cocaine Use Using Smart watches. Enrolled 19

CTN-0075 - Physician-Pharmacist Collaboration - OUD
Enrolled 37

Total Enrolled in all Studies: 24,849

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Naloxone Recall - Two Lots from Hospira Recalled Due to Particulate Matter

AlertThe Food and Drug Administration (FDA) is urging Naloxone carriers to check their product against a national recall list. The maker of the drug, Hospira, has issued a voluntary recall of the opioid overdose reversal drug Naloxone due to the presence of loose particulate matter in the syringe plunger.

Please inform the healthcare professionals in your network immediately. The FDA includes information on the specific product lot numbers affected by this recall.

Consumers call: 1-800-805-3093

Visit the FDA Recall Webpage for more information

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

News from the Nodes

Northeast Node

OV NodeNortheast Node Investigators receive $5.3M in PCORI funding to study medication-assisted treatment during pregnancy

Northeast Node Core Investigators Dr. Sarah Lord and Daisy Goodman have been approved for $5.3 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) to study medication-assisted treatment (MAT) models for pregnant women with opioid use disorder (OUD).

The study will span five years and look at three different types of MAT and obstetric treatment for pregnant women with OUD at 21 sites across Maine, New Hampshire, and Vermont. Many of these sites are partners or affiliates of the Northeast Node or work closely with its partners in the care of pregnant women with OUD.

The study will directly compare MAT programs that are integrated with obstetric care (or vice versa), and those that use referral-based services.

You can read an article about the exciting award here, published by the Geisel School of Medicine at Dartmouth College.

"The project was selected for PCORI funding for its potential to fill an important gap in our understanding of various medication-assisted treatment delivery models and to give pregnant women with opioid use disorder information that can help them weigh the effectiveness and safety of their care options," says PCORI Executive Director Joe Selby, MD, MPH. "We look forward to following the study’s progress and working with the Geisel researchers to share the results."

PCORI funding requires input from patients in every aspect of the project, including the application process. Together with the investigators, these patient advisory committee members have been able to help shape the project in a way that is both scientifically rigorous and practically relevant to informing models of care for pregnant women with OUD.

The team at the Northeast Node would like to extend our congratulations to the investigators, sites, and consultants/advisory committees for this important work!

Florida Node Alliance

On May 21, 2018, the CTN Florida Node Alliance co-sponsored a symposium titled, "Fighting Opioid Addiction: Integrating State of the Art Science Treatment into Patient Care."

The symposium featured presentations on the science of medication treatment for opioid addiction in non-traditional settings, and included participants from other CTN nodes, including keynote speaker Dr. Edward Nunes, from the Greater New York Node.

The event was livestreamed and recorded. Speaker excerpts can be found at: https://livestream.com/accounts/2263400/opiod

Pacific Northwest

OV NodeThe Pacific Northwest Node of the NIDA Clinical Trials Network is collaborating with the University of Washington Institute of Translational Health Sciences (ITHS) to announce the availability of consultation, services, and access to electronic health records data from 18 primary care clinics for substance use disorder focused research.

The PN Node aims to stimulate pilot projects that support new substance use disorder research in primary care practices from the WWAMI region (Washington, Wyoming, Alaska, Montana, Idaho).

The purpose of this opportunity is to provide investigators with primary care based electronic health record data for research related to the prevention, diagnosis, and treatment of substance use disorders. Data can be used for pilot projects that support development of large-scale research applications to NIDA in the area of substance use disorders. The PNW Node will help guide applicants to submit their large-scale research applications to NIDA Clinical Trial Network specific funding opportunities.

Applications are due July 20, 2018. Find out more about the award and application process here: https://www.iths.org/blog/news/funding/other-funding-opps/applications-open-service-voucher-to-explore-substance-use-disorders/

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

ICYMI (*In Case You Missed It)

Nora VolkowDr. Nora Volkow's Plenary at the 2018 CPDD Conference

NIDA Director Dr. Nora Volkow delivered a plenary presentation at the College on Problems of Drug Dependence (CPDD) meeting in San Diego, California, on June 13, 2018.

In a presentation titled "Drug Abuse & Addiction Research: Progress, Priorities, & Challenges," Dr. Volkow described current NIDA efforts in key areas of drug abuse research as well as priorities for future research.

View the slides of Dr. Volkow’s presentation

Social & Behavioral Research in Addressing the Opioid Crisis: Meeting Summary & Video

The NIH Office of Behavioral and Social Science Research (OBSSR), in collaboration with the National Institute on Drug Abuse (NIDA), the National Institute of Neurological Disorders and Stroke (NINDS), the National Center for Complementary and Integrative Health (NCCIH), the National Institute on Minority Health and Health Disparities (NIMHD), and the NIH Immediate Office of the Director (IMOD), hosted a meeting on March 5-6, 2018 to discuss social and behavioral contributions to address the opioid crisis. This meeting was part of the NIH HEAL (Helping to End Addiction Long-term) Initiative to help end the opioid crisis.

Check out the agenda, participant list, summaries, and videocasts from both days (scroll down to "Past Events").

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

From the Library

Impact of Behavioral Drug Abuse Treatment on Sexual Risk Behaviors: An Integrative Data Analysis of Eight Trials Conducted Within the National Drug Abuse Treatment Clinical Trials Network by Brown JL, et al. Prevention Science 2018 (in press).

Pharmacogenetic Analysis of Opioid Dependence Treatment Dose and Dropout Rates by Crist RC, et al. American Journal of Drug and Alcohol Abuse 2018;44(4):431-440.

New from the ATTC

ATTC Messenger June 2018
Psychosocial Supports During Buprenorphine Treatment in Specialty SUD Programs and Treatment Settings by Hannah K. Knudsen, PhD

ATTC/NIATx Service Improvement blog posts


Published by the CTN Dissemination Library of the Pacific Northwest Node
Alcohol & Drug Abuse Institute, University of Washington

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol & Drug Abuse Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

Unsubscribe | Subscribe

Copyright (C) 2016 Alcohol and Drug Abuse Institute. All rights reserved.